# Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months

> **NCT00453570** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 792 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Haemophilus Influenzae Type b
- Pertussis
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
- **BIOLOGICAL:** Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
- **BIOLOGICAL:** Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed

## Key facts

- **NCT ID:** NCT00453570
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 792 (ACTUAL)
- **Last updated:** 2012-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453570, "Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00453570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*